MAPT and Alzheimer disease: However, even when a similar method can be applied to both preclinical and post-mortem AD samples (e.g., immunohistochemical methods, single-cell RNA expression, tau PET), there often are important differences in the stage of disease/tau-pathological evolution when these methods are applied in the two different scenarios, potentially limiting the translatability.